Enliven Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-15.2%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.97next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly452.4MTarget: Sufficient to fund operations into the first half of 2029
ENABLE Phase 1 Trial Enrollment (ELVN-001) Quarterly161.0Target: Complete Phase 1b dose expansion and transition to Phase 3
Major Molecular Response (MMR) Rate at 24 Weeks (80 mg QD Cohort) Annually48.0%Target: Establish competitive efficacy profile vs. historical tyrosine kinase inhibitors
Watch Items
- Initiation of Phase 3 ENABLE-2 Pivotal Trial for ELVN-001Trigger: Second Half of 2026Action: Monitor regulatory filings and clinical trial registry updates for first patient dosed.
- Strategic Alternatives for ELVN-002 (HER2 Program)Trigger: Ongoing evaluationAction: Track corporate announcements regarding potential out-licensing, partnership, or spin-off to prioritize ELVN-001.
Research as of 19 Jun 2026